Norgine, an Amsterdam-based specialty pharmaceutical company, announced that Goldman Sachs Group Inc.’s private equity arm has agreed to buy a majority stake in the company from the Stein Family.
The financial terms of the deal weren’t disclosed. However, Bloomberg reports that the purchase values Norgine at about €1.8B. The Stein family will continue to own a significant stake in the company. The transaction is expected to complete in 2022, following the regulatory approvals.
Norgine was advised by Moelis & Company, Rothschild & Co, Latham & Watkins LLP, PwC, and Jamieson Corporate Finance.
Goldman Sachs Asset Management was advised by Goldman Sachs International – Investment Banking Division, Jefferies International Limited, White & Case LLP, and Deloitte LLP.